Colt Ventures

Alterome Therapeutics is a biotechnology company focused on precision oncology, specializing in the development of alteration-specific therapeutics aimed at treating cancer. By targeting high-value and validated oncogenic drivers, Alterome seeks to create innovative biopharmaceutical therapies that offer hope to individuals affected by cancer. The company's approach is centered on discovering and developing precise treatments that cater to the unique genetic alterations present in different cancer types, thereby enhancing the effectiveness of cancer therapies for healthcare providers and patients alike.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Alterome Therapeutics is a biotechnology company focused on precision oncology, specializing in the development of alteration-specific therapeutics aimed at treating cancer. By targeting high-value and validated oncogenic drivers, Alterome seeks to create innovative biopharmaceutical therapies that offer hope to individuals affected by cancer. The company's approach is centered on discovering and developing precise treatments that cater to the unique genetic alterations present in different cancer types, thereby enhancing the effectiveness of cancer therapies for healthcare providers and patients alike.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

EBY, LLC is a New York-based company that specializes in women's underwear and lingerie, offering a diverse range of products in various shapes and sizes. Founded in 2017, EBY operates on a membership model that includes a subscription service for delivering its intimate apparel. The company distinguishes itself by using patented flocking technology, which prevents sliding and riding of garments, enhancing the customer experience with lightweight fabric that provides a second-skin feel. EBY also emphasizes social impact by allocating 10% of its net sales to the Seven Bar Foundation, which empowers women out of poverty through microfinance loans, enabling them to start or grow their own businesses. This model aims to create a sustainable cycle of empowerment, helping women achieve self-sufficiency and break the cycle of poverty.

Rumble Inc. is a video management platform based in Toronto, Canada, established in 2013. It serves as an open video-sharing system for publishers and creators, allowing users to watch, share, and engage with videos. The platform enables users to upload their own content, including text, images, and videos, while also providing a rights management system to ensure proper licensing. Users can subscribe to channels to keep updated on new content and can access both on-demand videos and live streams from creators. The majority of Rumble's revenue is generated from the United States.

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for patients with cancers driven by the RAS/MAPK pathway. Founded in 2018, the company employs an artificial intelligence drug discovery platform known as OPRA, which utilizes machine learning to analyze large-scale data sets and identify novel tumor biology, thereby accelerating drug development. Erasca is developing a pipeline of oncology drugs, including Naporafenib, an innovative pan-RAF inhibitor aimed at treating NRAS-mutant melanoma and other RAS/MAPK-driven tumors. Additionally, the company is advancing ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor, targeting key nodes in the RAS/MAPK signaling pathway. Through its research and collaborations, Erasca aims to provide precision oncology options that offer potential solutions for treating and possibly curing cancer.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Bonti, Inc. is a biotechnology company focused on developing neurotoxin products for both aesthetic and therapeutic uses. The company specializes in botulinum neurotoxin serotype E, offering two primary products: EB-001A for aesthetic applications and EB-001T for therapeutic indications. Bonti aims to provide solutions for patients experiencing muscle hyperactivity and associated musculoskeletal pain, addressing unmet medical needs with a long-acting, non-opioid local muscle relaxant that minimizes side effects common with existing treatments. Founded in 2015, Bonti was originally known as Endurance Biotech, Inc. and changed its name in August 2015. The company is headquartered in Newport Beach, California, and operates as a subsidiary of Allergan plc.

Ignyta, Inc. is a biotechnology company focused on discovering, developing, and commercializing molecularly targeted therapies aimed at treating cancer and autoimmune diseases. Established in 2011 and based in San Diego, California, Ignyta is dedicated to advancing personalized medicine by integrating therapeutic approaches with companion diagnostics. Its notable products include entrectinib, a tyrosine kinase inhibitor targeting various receptor proteins, and RXDX-105, which is designed for RET-driven solid tumors. The company seeks to improve treatment outcomes by identifying patients most likely to benefit from specific therapies through biomarker-based diagnostics. In 2018, Ignyta became a subsidiary of Roche Holdings, further enhancing its capabilities in precision medicine.